

Algae Based Bio Compounds for Prevention and Treatment of Inflammation, Pain and IBD

Dorit Avni, MIGAL Galilee Research Institute, Israel

THE UNMET NEED OF IBD PATIENTS

More than 6.8 million kids and adults suffer from Inflammatory Bowel Disease (IBD), a chronic intestinal disorder that causes prolonged inflammation and damages the digestive tract. IBD prevalence is steadily increasing, yet no effective cure exists.

THE HEALTH POTENTIAL OF ALGAE

Marine and freshwater algae represent a largely unexplored yet promising resource for bio-active compounds. Both, micro and macro algae have been identified to produce small molecules and secondary metabolites with bio activity that could apply as a source against inflammation, pain and IBD.


Develop functional food, food supplements & novel drugs for IBD prevention and treatment.

Develop Algae4IBD BANK to expand the algae field by providing new knowledge.

GOALS


APPROACH

Microalgae



Macroalgae







Preventive approach-From Nature to plate

Treatment approach- From Nature to bedside







Identification of novel algae-based, anti-inflammatory compounds for lowcost commercial production at GMP grade.

EXELLENCE

multi-disciplinary consortium of algae production experts, gastroenterologists, functional food developers and pharma SMEs.

A holistic approach with state-of-the-art cultivation and extraction technologies, novel processing protocols that considers the whole value chain and guarantees the preservation of algae biodiversity.















Pharma industry


Food industry

Patients

Society

Investors

Policy makers



Improved patient well-being.

Reduced burden on hospitals.

Reduced healthcare costs for society.

IMPACT

Economic revenue for companies.











www.algae4ibd.eu

